$45.01
0.53% yesterday
Nasdaq, Dec 02, 10:00 pm CET
ISIN
US22663K1079
Symbol
CRNX

Crinetics Pharmaceuticals Inc Stock price

$45.01
+2.16 5.04% 1M
+13.13 41.19% 6M
-6.12 11.97% YTD
-12.38 21.57% 1Y
+26.59 144.35% 3Y
+32.08 248.11% 5Y
+20.50 83.64% 10Y
+20.50 83.64% 20Y
Nasdaq, Closing price Tue, Dec 02 2025
-0.24 0.53%
ISIN
US22663K1079
Symbol
CRNX
Industry

Key metrics

Basic
Market capitalization
$4.3b
Enterprise Value
$3.2b
Net debt
positive
Cash
$1.1b
Shares outstanding
94.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
2,773.4 | 812.9
EV/Sales
2,064.2 | 605.0
EV/FCF
negative
P/B
4.0
Financial Health
Equity Ratio
92.4%
Return on Equity
-22.5%
ROCE
-42.6%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$1.5m | $5.3m
EBITDA
$-474.2m | $-476.0m
EBIT
$-477.8m | $-510.2m
Net Income
$-423.1m | $-465.7m
Free Cash Flow
$-356.0m
Growth (TTM | estimate)
Revenue
48.1% | 405.2%
EBITDA
-55.7% | -41.6%
EBIT
-55.8% | -50.6%
Net Income
-52.2% | -56.1%
Free Cash Flow
-74.9%
Margin (TTM | estimate)
Gross
-
EBITDA
-30,890.2% | -9,059.9%
EBIT
-31,130.2%
Net
-27,563.3% | -8,864.0%
Free Cash Flow
-23,194.0%
More
EPS
$-4.5
FCF per Share
$-3.8
Short interest
19.1%
Employees
437
Rev per Employee
$0.0
Show more

Is Crinetics Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,085 stocks worldwide.

Crinetics Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

23 Analysts have issued a Crinetics Pharmaceuticals Inc forecast:

20x Buy
87%
3x Hold
13%

Analyst Opinions

23 Analysts have issued a Crinetics Pharmaceuticals Inc forecast:

Buy
87%
Hold
13%

Financial data from Crinetics Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
1.54 1.54
48% 48%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 166 166
87% 87%
10,767%
- Research and Development Expense 314 314
43% 43%
20,362%
-474 -474
56% 56%
-30,790%
- Depreciation and Amortization 3.68 3.68
63% 63%
239%
EBIT (Operating Income) EBIT -478 -478
56% 56%
-31,029%
Net Profit -423 -423
52% 52%
-27,474%

In millions USD.

Don't miss a Thing! We will send you all news about Crinetics Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Crinetics Pharmaceuticals Inc Stock News

Neutral
GlobeNewsWire
37 minutes ago
SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the first patient has been dosed in the Phase 1/2 study evaluating CRN09682 in patients with metastatic or locally advanced somatostatin receptor type 2 (SST2)-positive neuroendocrine tumors and other SST2-expressing solid tumors. CRN09682 is the lead candidate from Crinetics' proprietary...
Negative
The Motley Fool
6 days ago
Boston-based MPM BioImpact sold 428,975 shares of Crinetics Pharmaceuticals worth about $12.3 million in the third quarter. The move marked a full exit for MPM, which reported holding no shares of CRNX at quarter-end.
Neutral
GlobeNewsWire
13 days ago
CAREFNDR underscores the potential clinical value of p altusotine b eyond acromegaly, and demonstrates progress in Crinetics' commitment to addressing unmet needs in the neuroendocrine tumor community  SAN DIEGO, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc . (Nasdaq: CRNX) today announced the first patient has been randomized in the pivotal Phase 3 CAREFNDR trial, a multice...
More Crinetics Pharmaceuticals Inc News

Company Profile

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Head office United States
CEO Scott Struthers
Employees 437
Founded 2008
Website www.crinetics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today